We believe all people, particularly those who live with complex conditions, deserve new and better therapeutic options, and for the approximately 37,000 adult patients who have been diagnosed with idiopathic hypersomnia and are actively seeking care, this launch is a sign of hope the population has yet to see.
In recognition of International Lennox-Gastaut Syndrome (LGS) Awareness Day, which takes place every year on November 1, we sat down with Dr. Tracy Dixon-Salazar, Executive Director of the LGS Foundation, to discuss the importance of raising awareness of LGS – a developmental brain disorder that frequently evolves from early-life-onset epilepsy – and share her family’s personal journey with the disease.
By helping to bridge the gaps that can sometimes occur between academics and companies when conducting clinical translational research, the SU2C Catalyst program embodies the type of multisectoral partnerships that we at Jazz know are integral to addressing some of the largest hurdles in healthcare.
As part of our commitment to the cancer community, Jazz actively seeks out and listens to patients, physicians, care teams and advocacy groups for insights that could help develop new or better standards of care for rare and difficult-to-treat cancers.
Nothing Small About It is an online program from Jazz Pharmaceuticals – developed in consultation with CancerCare, GO2 Foundation for Lung Cancer, Lung Cancer Foundation of America and LUNGevity Foundation – as the first digital hub dedicated solely to SCLC patients and caregivers.
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.